Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer

Trial Profile

Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs Crizotinib (Primary) ; Itraconazole; Rifampicin
  • Indications Anaplastic large cell lymphoma; Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Acronyms PROFILE-1001
  • Sponsors Pfizer
  • Most Recent Events

    • 30 Oct 2018 Planned End Date changed from 1 Jul 2023 to 14 Jul 2023.
    • 30 Oct 2018 Planned primary completion date changed from 1 Jul 2023 to 14 Jul 2023.
    • 26 Sep 2018 Interim results (n=69, data cutoff: 31 Jan 2018) evaluating activity of Crizotinib in patients with Non-Small cell lung cancer were presented at the 19th World Conference on Lung Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top